Article Text

Download PDFPDF

1500 Integrated immunogenomic and digital histopathological analysis reveals correlation of immune landscape with the molecular subtypes in leiomyosarcoma
  1. Aditya Suru1,
  2. Alexandre Maalouf2,
  3. Lingling Chen1,
  4. Ada Tam3,
  5. William Villasi4,
  6. Lindy Zhang5,
  7. Meytal Guller1,
  8. Shivang Sharma1,
  9. Christian Meyer2,
  10. Jonathan Greer2,
  11. Fabian Johnston1,
  12. Carol Morris5,
  13. Sophia A Strike5,
  14. Adam Levin2,
  15. Daniel Rhee2,
  16. Brian Ladle2,
  17. Kornel Schuebel1,
  18. Yan Zhang1,
  19. Rulin Wang1,
  20. Srinivasan Yegnasubramanian2,
  21. John Gross5,
  22. Robert Anders6,
  23. Drew Pardoll2 and
  24. Nicolas Llosa5
  1. 1Johns Hopkins University, Baltimore, MD, USA
  2. 2Johns Hopkins University, School of Medicine, Baltimore, MD, USA
  3. 3Johns Hopkins University, Cockeysville, MD, USA
  4. 4Brooklyn College, New York, MD, USA
  5. 5Johns Hopkins Medicine, Baltimore, MD, USA
  6. 6Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Leiomyosarcoma (LMS) is one of the most common types of soft tissue sarcoma arising from the smooth muscle cells. Despite the current treatment regimens, many LMS patients experience progression and poor survival and might benefit from Immune Checkpoint Blockade (ICB). Yet LMS tumors have responded mildly to ICB. Deep immunogenomic profiling of LMS tumors might help in improving ICB outcomes by deconstructing the immune landscape to discover biomarkers of response and identify novel targets which might potentiate ICB outcomes in LMS.

Methods LMS tumors from The Cancer Genome Atlas (TCGA) Sarcoma cohort were classified into molecular subtypes based on previously identified gene signatures.1 We then examined the relationship of the subtypes with expression of various immune related genes. We comprehensively profiled the LMS immune landscape by performing Immunohistochemistry (IHC) (n = 65) for CD3, CD8, PDL1, CD163, TIM3, CD20, CD21 and CD31 on archived formalin fixed paraffin embedded blocks and multi-parameter flow cytometry (n = 22) on single cell suspensions isolated from LMS tumors resected at Johns Hopkins Hospital (JHH). We used HALO Digital Pathology Suite for further analysis.

Results LMS tumors from the TCGA cohort were classified into 4 major subtypes which associated with expression levels of the immune genes and survival outcomes. Based on the tissue slides available for the TCGA data, we observed presence of lymphoid aggregates predominantly in one subtype. IHC from the JHH cohort showed higher density of CD163 and PDL1 cells as compared to lymphoid cells and were associated with poor survival. We also observed aggregates of CD3 and CD8 cells and Tertiary Lymphoid Structures (TLS), as seen by CD21, CD20, CD3 IHC in a subset of specimens. Upon merging the different IHC for each specimen (n = 52) we saw a marked colocalization of PDL1 with the lymphoid aggregates hinting at the possibility of Interferon Gamma induced PDL1 expression. We noted high expression of PDL1 and TIM3 on myeloid cells which was correlated with poor survival outcomes.

Conclusions Deep immune profiling of the LMS specimens suggests that the TIM3 expressing myeloid cells could be a potential target to augment immunotherapy in LMS. Through spatial analysis, we observed a higher density of PDL1 cells around lymphoid aggregates as compared to the rest of the tumor pointing to evidence of immune related activity. Coupling our discoveries vis-à-vis the immune landscape to the molecular subtypes of LMS will be crucial to identify patients who will most benefit from ICB.


  1. ML Hemming, et al, Mol Cancer Res 2020;18(9):1302–1314

Ethics Approval This study was conducted in accordance with the ethical principles and was approved by the Johns Hopkins Institutional Review Board and all samples were obtained in accordance with the Health Insurance and Accountability Act.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.